Review of the Therapeutic Uses of Liraglutide

Ryan, Gina J.; Foster, Karla T.; Jobe, Lynetta J.

doi:10.1016/j.clinthera.2011.06.004

Cited by 34 publications

(34 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, GLP-1 analogues are recommended in the "therapeutic climbing" generally in association with a biotherapy or insulin, when first-line oral anti-diabetics, such as metformin or sulfonylureas, are not efficient enough to reduce the HbA1c level to the therapeutic target (8).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide

Soudahome

Catan

Giraud

et al. 2018

Journal of Biological Chemistry

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Consequently, liraglutide requires only once-daily subcutaneous injection. Like native GLP-1, liraglutide triggers insulin secretion, inhibits postprandial glucagon secretion, retards gastric emptying and enhances satiety by acting on the brain (7,8).…”

Section: Introductionmentioning

confidence: 99%

Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide

Soudahome

Catan

Giraud

et al. 2018

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…Following its secretion from the intestinal L-cells, GLP-1 binds to its receptor (GLP-1R) on pancreatic β-cells to stimulate insulin secretion (19). As GLP-1 is quickly degraded in the circulation by the ubiquitous protease dipeptidyl peptidase-IV (DPP-4), GLP-1 agonists with an extended half-life by virtue of their resistance to degradation by DPP-4 have been developed for clinical use (21), including Exendin-4 (Ex-4) and Liraglutide (LIR) (22,23). GLP-1 agonists, administered either as a monotherapy or in combination with other existing oral anti-diabetic drugs (24), are now increasingly used for the treatment of DM, as they provide additional extra-glycaemic effects, such as weight loss (25).…”

Section: Introductionmentioning

confidence: 99%

Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice

Pereira

Jeyabalan

Jorgensen

et al. 2015

Bone

View full text Add to dashboard Cite

“…47 Mild to moderate nausea and vomiting are the main side effects of liraglutide, which are often transient. Although nausea may contribute to weight loss, the combined effects on energy intake and energy expenditure are the most widely accepted mechanisms for liraglutide caused weight control.…”

Section: Discussionmentioning

confidence: 99%

Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats

Zheng

Chen

Zhu

et al. 2015

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

We reported recently that after a nutritional growth retardation, rats showed significant weight gain, central fat accumulation, dyslipidemia, and b-cell dysfunction during a catch-up growth (CUG) phase. Here, we investigated whether glucagon-like peptide-1 (GLP-1) ameliorated the rapid weight gain, central fat deposition, and b-cell dysfunction during the CUG in rats. Sixty-four male Sprague Dawley rats were stratified into four groups including normal control group, CUG group, catch-up growth with liraglutide treatment group, and catch-up growth with liraglutide and exendin 9-39 treatment group. Energy intake, body weight, and body length were monitored. Fat mass percentage was analyzed by dual energy X-ray absorptiometry scan. Plasma triglyceride and non-esterified fatty acid were measured. The b-cell mass was analyzed by morphometric analysis and signaling molecules were examined by Western blot and real-time PCR. Insulin secretion capability was evaluated by hyperglycemic clamp test. Liraglutide prevented weight gain and improved lipid and glucose metabolism in rats under CUG conditions, which were associated with reduced fasting insulin levels and improved glucose-stimulated insulin secretion. Improved b-cell function is found to be associated with increased b-cell replication as determined by b-cell density and insulin-Ki67 dual staining. Furthermore, liraglutide increased islet pancreatic duodenal homeobox-1 (Pdx-1) and B-cell lymphoma-2 transcript and protein expression, and reduced Procaspase-3 transcript and Caspase-3 p11 subunit protein expression, suggesting that expression of Pdx-1 and reduction of apoptosis may be the mechanisms involved. The therapeutic effects were attenuated in rats co-administered with exendin 9-39, suggesting a GLP-1 receptor-dependent mechanism. These studies revealed that incretin therapy effectively prevented fast weight gain and b-cell dysfunction in rats under conditions of nutrition restriction followed by nutrition excess, which is in part due to enhanced functional b-cell mass and insulin secretory capacity.

show abstract

Review of the Therapeutic Uses of Liraglutide

Cited by 34 publications

References 75 publications

Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide

Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide

Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomised mice

Liraglutide prevents fast weight gain and β-cell dysfunction in male catch-up growth rats

Contact Info

Product

Resources

About